Drug Profile

64Cu SAR bisPSMA - Clarity Pharmaceuticals

Alternative Names: ⁶⁴Cu SAR bisPSMA; Cu-64 SAR-bisPSMA

Latest Information Update: 17 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Clarity Pharmaceuticals
Class Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics
Mechanism of Action Positron-emission tomography enhancers

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase III Prostate cancer

Most Recent Events

13 Oct 2025 Efficacy data from a phase II trial in Prostate cancer released by Clarity Pharmaceuticals
21 Jul 2025 Clarity Pharmaceuticals completes enrolment in a phase II trial in Prostate cancer (Diagnosis) in Australia (NCT06907641)
17 Jun 2025 Clarity Pharmaceuticals and SpectronRx enters into a manufacturing agreement to produce 64Cu-SAR-bisPSMA

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com